CryoPort (CYRX) Upgraded to Buy: Here's Why
CryoPort (CYRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
CYRX - Cryoport, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$18.79
DETAILS
HIGH:
$25.00
LOW:
$13.50
MEDIAN:
$19.00
CONSENSUS:
$18.79
UPSIDE:
13.40%
Stock News
Cryoport, Inc. (CYRX) Q2 2026 Earnings Call Transcript
Cryoport, Inc. (CYRX) Q2 2026 Earnings Call Transcript
CryoPort Q2 Earnings Call Highlights
CryoPort NASDAQ: CYRX reported second-quarter 2026 revenue of $49 million and said it reached positive adjusted EBITDA from continuing operations, while reaffirming its full-year revenue outlook of $192 million to $196 million.
CryoPort, Inc. (CYRX) Reports Q2 Loss, Beats Revenue Estimates
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.2 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.29 per share a year ago.
Cryoport Reports Second Quarter 2026 Financial Results
Second quarter revenue grew 8% year-over-year to $49.0 million Life Sciences Services revenue increased 15% year-over-year BioStorage/BioServices revenue grew 25% year-over-year Supporting 779 global clinical trials and 22 commercially approved cell and gene therapies (CGT) as of June 30, 2026 NASHVILLE, Tenn., Aug. 6, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and first half (H1) of 2026.
Cryoport to Report Second Quarter 2026 Financial Results on August 6, 2026
NASHVILLE, Tenn., July 23, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the second quarter ended June 30, 2026 on Thursday, August 6, 2026 after U.S. markets close.
Cryoport's IntegriCell® Cryopreservation Services Selected by Verismo Therapeutics to Support Clinical KIR-CAR T Cell Therapy Programs
IntegriCell Provides Process Development, Technology Transfer, and Clinical Cryopreservation Services Supporting Verismo's Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and SynKIR™-310 NASHVILLE, Tenn., June 25, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that Cryoport Systems' IntegriCell® cryopreservation services have been selected by Verismo Therapeutics, a clinical-stage CAR T cell therapy company pioneering a novel multi-chain KIR-CAR platform technology for the treatment of solid tumors (SynKIR™-110) and B cell associated disorders and malignancies (SynKIR™-310).
Cryoport, Inc. (CYRX) Q1 2026 Earnings Call Transcript
Cryoport, Inc. (CYRX) Q1 2026 Earnings Call Transcript
CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.22 per share a year ago.
Cryoport Reports First Quarter 2026 Financial Results
First quarter revenue grew 16% year-over-year to $47.8 million Commercial cell and gene therapy (CGT) revenue grew 26% year-over-year to $9.1 million, reflecting continued expansion in approved CGT programs Life Sciences Services revenue increased 18% year-over-year, led by 21% growth in BioStorage/BioServices Life Sciences Products revenue increased 15% year-over-year, driven by strong demand for cryogenic systems Supporting a record 766 global clinical trials and 21 commercially approved CGTs as of March 31, 2026 Company raises full-year revenue guidance to $192 million - $196 million NASHVILLE, Tenn., May 4, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its first quarter (Q1) of 2026.
Cryoport to Report First Quarter 2026 Financial Results on May 4, 2026
NASHVILLE, Tenn., April 20, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the first quarter ended March 31, 2026 on Monday, May 4, 2026 after U.S. markets close.
Cryoport: Moving Toward Commercial Scalability And Near-Term Breakeven
Cryoport receives a buy rating with a $9.1 price target, implying 17% upside by FY 2026. CYRX demonstrated double-digit revenue growth in Q4 2025, led by Life Sciences Services, and improved gross margins to 47.8%. Management targets positive adjusted EBITDA in H2 2026, supported by cost reductions and a strengthened partnership with DHL.
CryoPort, Inc. (NASDAQ:CYRX) Receives Average Recommendation of “Moderate Buy” from Brokerages
CryoPort, Inc. (NASDAQ: CYRX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the ten brokerages that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have given a buy recommendation to the
Cryoport, Inc. (CYRX) Q4 2025 Earnings Call Transcript
Cryoport, Inc. (CYRX) Q4 2025 Earnings Call Transcript
CryoPort, Inc. (CYRX) Reports Q4 Loss, Tops Revenue Estimates
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.42 per share a year ago.
Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results
FY 2025 revenue increased to $176.2 million, exceeding the high end of previous guidance Life Sciences Services revenue grew 18% year-over-year in FY 2025, including a 22% rise in BioStorage/BioServices revenue Commercial cell and gene therapy revenue increased 29% year-over-year to $33.4 million in FY 2025 Supported a record 760 global clinical trials and 20 commercially approved therapies as of December 31, 2025 Full-year 2026 revenue guidance of $190 million to $194 million (8%-10% growth y-o-y) NASHVILLE, Tenn., March 3, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its fourth quarter (Q4) and year ended (FY) December 31, 2025.
Cryoport to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
NASHVILLE, Tenn., Feb. 17, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2025 on Tuesday, March 3, 2026 after U.S. markets close.
Cryoport's MVE Biological Solutions Introduces New Fusion® 800 Series
Self-Sustaining Fusion® 800 Series Cryogenic Freezer Delivers High-Capacity Storage, Flexibility, and Cost Benefits in Limited Space Environments NASHVILLE, Tenn., Feb. 11, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced the launch of the MVE Fusion® 800 Series, the next evolution of MVE Biological Solutions' patented, award-winning Fusion technology.
EXCLUSIVE: New Fusion 800 Launch Signals Cryoport's Ambition To Modernize Cryogenic Storage
Cryoport, Inc. launched the Fusion 800 Series, a compact cryogenic storage system that eliminates the need for continuous liquid nitrogen. Revenue grew 15% in Q3, and fiscal 2025 revenue guidance was raised to $170-174 million.
CryoPort (NASDAQ:CYRX) vs. Royal Mail (OTCMKTS:ROYMY) Head-To-Head Contrast
CryoPort (NASDAQ: CYRX - Get Free Report) and Royal Mail (OTCMKTS:ROYMY - Get Free Report) are both transportation companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation. Institutional and Insider Ownership 92.9% of CryoPort shares are
Price Targets
Cryoport price target raised to $19 from $15 at Needham
$19.00
(was $14.71)
Needham
Cryoport price target raised to $16 from $12 at Guggenheim
$16.00
(was $14.71)
Subbu Nambi
·
Guggenheim
Cryoport price target raised to $21 from $15 at Roth Capital
$21.00
(was $14.71)
Richard Baldry
·
Roth Capital
Cryoport price target raised to $25 from $17 at BTIG
$25.00
(was $16.03)
BTIG
Cryoport price target raised to $13.50 from $11 at Jefferies
$13.50
(was $15.48)
Matthew Stanton
·
Jefferies
Cryoport price target raised to $13 from $11 at Jefferies
$13.00
(was $15.48)
Matthew Stanton
·
Jefferies
Cryoport price target raised to $20 from $15 at Craig-Hallum
$20.00
(was $16.10)
Matthew Hewitt
·
Craig-Hallum
Cryoport price target raised to $17 from $15 at KeyBanc
$17.00
(was $13.03)
Paul Knight
·
KeyBanc
Cryoport price target raised to $15 from $13 at Needham
$15.00
(was $12.14)
Needham
Cryoport price target raised to $17 from $15 at BTIG
$17.00
(was $10.21)
BTIG
Cryoport price target raised to $12 from $11 at Guggenheim
$12.00
(was $10.21)
Subbu Nambi
·
Guggenheim
Cryoport price target raised to $12.50 from $11 at UBS
$12.50
(was $8.75)
UBS
Cryoport price target raised to $15 from $10 at BTIG
$15.00
(was $8.90)
BTIG
Cryoport price target raised to $11 from $10 at UBS
$11.00
(was $6.09)
UBS
Cryoport upgraded to Buy from Neutral at UBS
$10.00
(was $7.10)
UBS
Cryoport initiated with a Buy at Guggenheim
$11.00
(was $7.62)
Subbu Nambi
·
Guggenheim
Cryoport downgraded to Hold at Jefferies on diminished growth outlook
$8.00
(was $7.79)
Matthew Stanton
·
Jefferies
B.Riley Upgrades CryoPort (CYRX) to Buy
$15.00
(was $9.05)
Yuan Zhi
·
B.Riley Financial
B.Riley Downgrades CryoPort (CYRX) to Neutral
$19.00
(was $15.95)
Yuan Zhi
·
B.Riley Financial
Jefferies Assumes CryoPort (CYRX) at Buy, 'Thesis Refresh'
$21.00
(was $18.34)
Matthew Stanton
·
Jefferies